Emergence of HIV-1 drug resistance mutations among antiretroviral-naïve HIV-1-infected patients after rapid scaling up of antiretroviral therapy in Thailand by Sungkanuparph, Somnuek et al.
RESEARCH Open Access
Emergence of HIV-1 drug resistance mutations
among antiretroviral-naïve HIV-1-infected patients
after rapid scaling up of antiretroviral therapy in
Thailand
Somnuek Sungkanuparph
1*, Chonlaphat Sukasem
2, Sasisopin Kiertiburanakul
1, Ekawat Pasomsub
2 and
Wasun Chantratita
2
Abstract
Background: After rapid scaling up of antiretroviral therapy in HIV-1-infected patients, the data of primary HIV-1
drug resistance in Thailand is still limited. This study aims to determine the prevalence and associated factors of
primary HIV-1 drug resistance in Thailand.
Methods: A prospective observational study was conducted among antiretroviral-naïve HIV-1-infected Thai patients
from 2007 to 2010. HIV-1 subtypes and mutations were assayed by sequencing a region of HIV-1 pol gene.
Surveillance drug resistance mutations recommended by the World Health Organization for surveillance of
transmitted HIV-1 drug resistance in 2009 were used in all analyses. Primary HIV-1 drug resistance was defined as
the presence of one or more surveillance drug resistance mutations.
Results: Of 466 patients with a mean age of 38.8 years, 58.6% were males. Risks of HIV-1 infection included
heterosexual (77.7%), homosexual (16.7%), and intravenous drug use (5.6%). Median (IQR) CD4 cell count and HIV-1 RNA
were 176 (42-317) cells/mm
3 and 68,600 (19,515-220,330) copies/mL, respectively. HIV-1 subtypes were CRF01_AE
(86.9%), B (8.6) and other recombinants (4.5%). The prevalence of primary HIV-1 drug resistance was 4.9%; most of these
(73.9%) had surveillance drug resistance mutations to only one class of antiretroviral drugs. The prevalence of patients
with NRTI, NNRTI, and PI surveillance drug resistance mutations was 1.9%, 2.8% and 1.7%, respectively. From logistic
regression analysis, there was no factor significantly associated with primary HIV-1 drug resistance. There was a trend
toward higher prevalence in females [odds ratio 2.18; 95% confidence interval 0.896-5.304; p = 0.086].
Conclusions: There is a significant emergence of primary HIV-1 drug resistance in Thailand after rapid scaling up of
antiretroviral therapy. Although HIV-1 genotyping prior to antiretroviral therapy initiation is not routinely
recommended in Thailand, our results raise concerns about the risk of early treatment failure in patients with
primary HIV-1 drug resistance. Interventions to prevent the transmission of HIV-1 drug resistance and continuation
of surveillance for primary HIV-1 drug resistance in Thailand are indicated.
Background
In Thailand, the disease burden from HIV/AIDS resulting
from the epidemic in the 1990s remains high [1]. Although
the incidence rate of HIV-1 infection in Thailand from
2001 to 2009 has decreased by more than 25% [2], the
accumulated number of HIV-1-infected persons is still
high. Currently, an estimated 530,000 people are living
with HIV in Thailand [2]. Combination antiretroviral ther-
apy (ART) has significantly reduced mortality and morbid-
ity since its introduction in Thailand [3-5]. Since 2001, the
government has committed to providing ART free of
charge to people living with HIV under the National
Access to Antiretroviral Program for People Living with
HIV/AIDS (NAPHA) [6]. The subsequent production and
* Correspondence: somnuek.sun@mahidol.ac.th
1Division of Infectious Diseases, Department of Medicine, Faculty of
Medicine Ramathibodi Hospital, Mahidol University, Bangkok, Thailand
Full list of author information is available at the end of the article
Sungkanuparph et al. Journal of the International AIDS Society 2012, 15:12
http://www.jiasociety.org/content/15/1/12
© 2012 Sungkanuparph et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative
Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
reproduction in any medium, provided the original work is properly cited.use of generic drugs led to more than an eight-fold expan-
sion in treatment provision between 2001 and 2003 [7].
Since 2006, with rapid growth of NAPHA, it has been
transformed into the National AIDS Program under the
management of the National Health Security Office.
According to the UNAIDS 2010 report, 216,118 persons
were receiving ART in December 2009, and the number of
life years among adults gained due to ART between 1996
and 2009 is 389,000 [2].
Despite these successes, HIV-1 drug resistance
(HIVDR) is a major reason for treatment failure during
rapid scaling up of ART in Thailand [8,9]. According to
the Thai national treatment guidelines, non-nucleoside
reverse transcriptase inhibitor (NNRTI)-based regimens
are recommended as first-line regimens [10]. Approxi-
mately 5% to 10% of patients receiving ART have experi-
enced treatment failure and HIVDR [10]. Previous survey
studies in Thailand had shown low prevalence of trans-
mitted HIVDR among Thai patients with early HIV-1
infection [11,12]. Recently, a study in Thailand demon-
strated the transmission of HIVDR in antiretroviral-naïve
HIV-1-infected patients [13]. This threatens the effective-
ness of rapidly scaled up first-line ART in the country.
Primary HIVDR means that there is increased resistance
of HIV-1 to antiretroviral drugs seen in individuals who
have never received ART and presumably have been
infected with a drug-resistant virus [14]. The prevalence of
primary HIVDR has been well reported in the United
States and Europe, and ranges from 6.2% to 21% [15-18].
A study in Asia has recently reported the prevalence of
primary HIVDR at 13.8% [19]. In resource-limited settings
where ART is being scaled up, the World Health Organi-
zation (WHO) recommends the surveillance of primary
HIVDR [20]. To date, after a decade of ART scaling up,
there is limited published information regarding primary
HIVDR in Thailand. This study was aimed at determining
the prevalence of HIVDR and associated factors among
antiretroviral-naïve patients in Thailand.
Methods
A cross-sectional study was conducted among antiretro-
viral-naïve HIV-1-infected patients who recently visited
the Infectious Disease Clinic at Ramathibodi Hospital, a
university hospital, between January 2007 and December
2010. This clinic primarily serves patients from Bangkok
and its peripheral areas. Patients with a history of any
exposure to antiretroviral drugs, including mono or dual
therapy, or prevention of mother to child transmission,
were excluded. Ethics approvals were obtained from local
institutional review boards. Informed consent was
obtained prior to genotypic resistance testing.
All plasma samples, HIV-1 pol nucleotide sequencing of
reverse transcriptase and protease region was carried out
using TRUGENE HIV-1 Genotypic Assay in conjunction
with the Open Gene automated DNA sequencing system
(Visible Genetics, Toronto, Canada). Testing involved
simultaneous clip sequencing of protease and codons 35-
244 of the RT from the amplified cDNA in both the 3’ and
5’ directions. Sequences were aligned and compared with a
lymphoadenopathy-associated virus type 1 (HIV-B-LAV1)
consensus sequence using Visible Genetics Gene Librarian
software [21,22]. Genotypic HIV-1drug resistance testing
was performed with externally quality controlled. Subtype
was determined on the basis of genotyping of pol gene.
Surveillance drug resistance mutations (SDRMs) recom-
mended by WHO for surveillance of transmitted HIVDR
in 2009 [23] were used in all analyses. HIVDR in a patient
was defined as the presence of at least one SDRM.
Mean (± standard deviation, SD), median (interquartile
range, IQR) and frequencies (%) were used to describe
patients’ characteristics. Categorical variables between the
two groups were compared using Chi square or Fisher’s
exact test as appropriate. Continuous variables between
the two groups were compared using Student’s t test and
Mann-Whitney U test as appropriate. Logistic regression
analysis was used to determine factors associated with
HIVDR. A p value of < 0.05 was considered to be statisti-
cally significant. All analyses were performed using SPSS
version 16.0 (SPSS Inc., Chicago, Illinois, USA).
Results
A total of 466 patients were included in this analysis. The
mean (SD) age was 38.8 (11.4) years. In total, 263 (58.6%)
patients were males. Risks of HIV-1 infection were hetero-
sexual (77.7%), homosexual (16.7%), and intravenous drug
use (5.6%). Forty-six (9.9%) and 32 (6.9%) patients had co-
infection of hepatitis B virus and hepatitis C virus, respec-
tively. Median (IQR) CD4 cell count and HIV-1 RNA
were 176 (42-317) cells/mm
3 and 68,600 (19,515-220,330)
copies/mL, respectively. Of 466 patients, 405 (86.9%) were
infected with HIV-1 subtype CRF01_AE. Subtype B was
found in 40 (8.6) patients. Other subtypes (4.5%) were
CRF07_BC, CRF03_AB, CRF02_AG, CRF12_BF, D and K.
The prevalence of primary HIVDR was 4.9%. The preva-
lence of patients with nucleoside reverse transcriptase
inhibitor (NRTI), NNRTI and protease inhibitor (PI)
SDRMs was 1.9%, 2.8% and 1.7%, respectively. Seventeen
(3.8%) patients had at least one SDRM to only one class of
antiretroviral drugs. Five (1.1%) patients had both NRTI
and NNRTI SDRMs. Only one patient had SDRMs to
three classes of antiretroviral drugs. Table 1 shows
SDRMs observed in 23 patients with HIVDR. The com-
parison of characteristics between patients with and with-
out HIVDR is summarized in Table 2. From logistic
regression analysis, there was no factor significantly asso-
ciated with HIVDR. There was a trend toward higher
prevalence in females [OR = 2.18; 95% CI 0.896-5.304;
p = 0.086].
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Primary HIVDR represents a challenge for the treatment
of HIV-1 infection because it can reduce the efficacy of
first-line ART and may impact clinical outcomes. Emer-
gence of primary HIVDR in resource-limited settings is a
concerning consequence of global scaling up of ART. It is
established that primary HIVDR will emerge in the region
where ART has been widely available for years [20]. After
a decade of rapid scaling up of ART in Thailand, primary
HIVDR is inevitably anticipated.
The results from the present study have demonstrated
that there is an emergence of primary HIVDR in Thai-
land. The prevalence of primary HIVDR in the present
study is 4.9%, approaching WHO’s first threshold (5%) of
transmitted HIVDR. Previous studies had predicted that
transmitted HIVDR would reach 5% after approximately
10 years of ART scaling up [20,24]. Although the term,
“transmitted HIVDR”, is generally applied only to
HIVDR detected in recently infected individuals, the pre-
valence of primary HIVDR among patients with chronic
HIV-1 infection may be even underestimated. Thus, the
r e s u l t sf r o mt h ep r e s e n ts t u d yp r o v i d ed a t aa b o u tt h e
likely efficacy of first-line ART in Thailand. For example,
the prevalence of primary HIVDR at 4.9% indicates that
about 5% of patients initiating first-line ART in Thailand
may have early treatment failure. NNRTI-based regi-
mens, which are preferred regimens for first-line ART in
Thailand, generally have low genetic barriers for develop-
ment of resistance, and early treatment failure is likely if
the regimen does not consist of three fully active drugs
[25,26].
NNRTI SDRMs, M184V and thymidine analogue-asso-
ciated mutations (TAMs) are the most common SDRMs
observed in the present study. These mutations are com-
monly found in patients failing NNRTI-based regimens,
such as zidovudine/lamivudine/nevirapine and zidovu-
dine/lamivudine/efavirenz, which are widely used as first-
line ART in Thailand [9]. Recently, various multicentre
cohort studies have demonstrated that primary HIVDR is
associated with poor treatment outcomes and/or clinical
complication [27-29]. They all support the use of genoty-
pic resistance test prior to initiation of ART.
Since 1998, the International AIDS Society-USA Panel
had suggested considering resistance testing for antiretro-
viral-naïve patients in areas with a prevalence of resistance
of ≥ 5% [30]. However, a cost-effectiveness study of geno-
typic resistance testing for antiretroviral-naïve patients
with chronic HIV-1 infection has reported that it is cost
effective if the prevalence of primary HIVDR is more than
1% [31].
Thailand is an area with predominance of HIV-1 subtype
CRF01_AE. Although the prevalence of HIVDR in patients
with subtype CRF01_AE is twice that of patients with sub-
type B in the present study, there was no statistically signif-
icant difference. There were also no significant differences
in demographic or clinical factors between those with and
without primary HIVDR. There was only a trend toward
higher prevalence in females from multivariate analysis.
Therefore, there is no risk group to consider genotypic
testing for primary HIVDR in Thailand. A recent study has
shown that ART-naïve patients older than 25 years exhib-
ited significantly higher prevalence of primary HIVDR than
younger patients [32]. However, there was no difference of
the prevalence of primary HIVDR between these two age
groups in the present study.
As ART continues to be scaled up rapidly, it is likely
that the prevalence of primary HIVDR continues to
Table 1 Distribution of SDRMs in 23 patients with
primary HIVDR*
SDRMs Number of patients Prevalence (%)
NRTI-SDRMs 9 1.9
M41L 3 0.6
K65R 1 0.2
D67N 1 0.2
T69D 1 0.2
V75M 1 0.2
M184V 3 0.6
M184I 1 0.2
L210W 1 0.2
T215Y 1 0.2
T215S 1 0.2
K219Q 1 0.2
K219R 1 0.2
NNRTI-SDRMs 13 2.8
K101E 1 0.2
K103N 3 0.6
K103S 1 0.2
V106A 1 0.2
V106M 1 0.2
Y181C 4 0.9
Y181I 1 0.2
Y188L 1 0.2
G190S 1 0.2
PI-SDRMs 8 1.7
M46I 1 0.2
M46L 1 0.2
I47V 1 0.2
G48M 1 0.2
I54L 1 0.2
I54T 1 0.2
I84A 1 0.2
L90M 6 1.3
*some patients had more than one SDRM
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further transmission of HIVDR. To minimize primary
HIVDR in Thailand, strengthening the healthcare sys-
tem, supporting adherence to therapy, and ensuring a
continuous supply of antiretroviral drugs are crucial. At
some point, the National AIDS Program in Thailand has
to carefully consider the advantages and disadvantages
of genotypic testing for primary HIVDR and decide
when and how to implement. Future plans have to
include strategies to make genotypic testing more acces-
sible with the newer technologies, such as point muta-
tion assays or short sequencing of a specific region of
RT gene.
There are some limitations in the present study.
Although the patients in this study were those who
newly presented to the infectious disease clinic, some
patients presented late. They were tested for HIV-1 gen-
otypes at the stage of chronic infection. Some resistance
mutations may have reverted to wild type. Thus, the
prevalence of primary HIVDR could be underestimated.
However, transmitted HIVDR among antiretroviral-
naïve patients has been reported to be persistent, ran-
ging from four years to longer than the lifetime of the
patient [33]. The prolonged persistence of transmitted
HIVDR strongly supports the use of a genotypic resis-
tance test in newly presented patients.
Conclusions
Primary HIVDR is emerging in Thailand after a decade
of rapid scaling up of ART. Although HIV-1 genotyping
prior to ART initiation is not routinely recommended in
Thailand, continuation of surveillance for primary
HIVDR in Thailand is indicated. Public health interven-
tions to prevent the transmission of HIVDR should be
implemented on a large scale.
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